Immunizations used to treat COVID-19, respiratory syncytial virus (RSV) and influenza safely reduce the risk of adverse outcomes among people of all ages, according to a systematic analysis of 511 ...

The adjusted pooled incidence of RSV among preschool children in primary care settings was 62.8 per 1,000 people in the ...

EDP-323 significantly reduced mean viral load AUC by 85% and 87% in the high- and low-dose groups, respectively, compared ...

People who caught the flu were up to six times more likely to have a heart attack in the month after the infection.

("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure chronic conditions ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States, sending greater ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral ...